AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11689736 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal exercise testing and ABPI measurement in trained cyclists with EILP
Number of subjects: 32
Study 11689736 — intervention group
Group type: COMPARATOR
Intervention: Maximal exercise testing and ABPI measurement in untrained individuals
Number of subjects: 32
Study 11689736 — intervention group
Group type: COMPARATOR
Intervention: Maximal exercise testing and ABPI measurement in trained cyclists without EILP
Number of subjects: 32
Study 9135831 — intervention group
Group type: EXPERIMENTAL
Intervention: Branded salbutamol (Ventolin)
Number of subjects: 29
Study 9135831 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinded Ventolin
Number of subjects: 29
Study 9135831 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic salbutamol
Number of subjects: 29
Study 9135831 — intervention group
Group type: COMPARATOR
Intervention: Patient assessment of inhalers
Number of subjects: 29
Study 8075195 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening detected cancers
Number of subjects: 324
Study 8075195 — intervention group
Group type: EXPERIMENTAL
Intervention: Node positive cases
Number of subjects: 324
Study 8075195 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole series
Number of subjects: 324
Study 8075195 — intervention group
Group type: COMPARATOR
Intervention: Clinically detected cancers
Number of subjects: 324
Study 3296629 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral rehydration
Number of subjects: 37
Study 3296629 — intervention group
Group type: COMPARATOR
Intervention: Intravenous rehydration
Number of subjects: 37
Study 30076156 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab plus methotrexate
Number of subjects: 0
Study 30076156 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate monotherapy
Number of subjects: 0
Study 28768785 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA) 1000 mg intravenously
Number of subjects: 54
Study 28768785 — intervention group
Group type: COMPARATOR
Intervention: Placebo (100 ml saline)
Number of subjects: 54
Study 25883164 — intervention group
Group type: EXPERIMENTAL
Intervention: DialBetics with FoodLog
Number of subjects: 5
Study 22905971 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic education programme for twelve weeks
Number of subjects: 48
Study 21750006 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower levels of physical activity (RR, 0.68 for high versus low)
Number of subjects: 27791
Study 21750006 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater body mass index (BMI; RR, 2.14 for ≥35 versus 19.5-24.9 kg/m²)
Number of subjects: 27791
Study 21750006 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater height (RR, 2.04 for >66 versus ≤62 inches)
Number of subjects: 27791
Study 21750006 — intervention group
Group type: EXPERIMENTAL
Intervention: History of uterine fibroids (RR, 1.72)
Number of subjects: 27791
Study 19634510 — intervention group
Group type: EXPERIMENTAL
Intervention: Test preparation (clopidogrel 75 mg)
Number of subjects: 48
Study 19634510 — intervention group
Group type: COMPARATOR
Intervention: Reference preparation (clopidogrel 75 mg)
Number of subjects: 48
Study 19634510 — intervention group
Group type: EXPERIMENTAL
Intervention: Test preparation (CBS)
Number of subjects: 48
Study 19634510 — intervention group
Group type: COMPARATOR
Intervention: Reference preparation (CBS)
Number of subjects: 48
Study 16942589 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin GITS 4 mg q.i.d.
Number of subjects: 165
Study 16942589 — intervention group
Group type: COMPARATOR
Intervention: Tamsulosin 0.4 mg q.i.d.
Number of subjects: 165
Study 15506598 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-piece acrylic IOL
Number of subjects: 493
Study 15506598 — intervention group
Group type: COMPARATOR
Intervention: Single-piece acrylic IOL
Number of subjects: 493
Study 11356438 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg mifepristone followed by 400 mg oral misoprostol (home administration)
Number of subjects: 315
Study 11356438 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg mifepristone followed by 400 mg oral misoprostol (clinic administration)
Number of subjects: 315
Study 9236560 — intervention group
Group type: EXPERIMENTAL
Intervention: VLED + BT
Number of subjects: 59
Study 9236560 — intervention group
Group type: COMPARATOR
Intervention: BT
Number of subjects: 59
Study 8204244 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 micrograms/kg of preservative‐free epidural morphine with 40 micrograms/kg of butorphanol
Number of subjects: 20
Study 8204244 — intervention group
Group type: COMPARATOR
Intervention: 80 micrograms/kg of preservative‐free epidural morphine
Number of subjects: 20
Study 3074603 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen (100 mg)
Number of subjects: 8
Study 3074603 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen sodium (500 mg)
Number of subjects: 8
Study 3074603 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 8
Study 29982957 — intervention group
Group type: EXPERIMENTAL
Intervention: Vocational Advice Intervention (VAI) delivered by trained physiotherapists
Number of subjects: 0
Study 29982957 — intervention group
Group type: EXPERIMENTAL
Intervention: Training and mentoring package for Vocational Advisors (VAs)
Number of subjects: 0
Study 28928110 — intervention group
Group type: EXPERIMENTAL
Intervention: eHealth self‐management intervention (website and mobile phone app)
Number of subjects: 60
Study 26027866 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D computer-aided planning approach
Number of subjects: 0
Study 26027866 — intervention group
Group type: COMPARATOR
Intervention: 2D planning technique
Number of subjects: 0
Study 24330729 — intervention group
Group type: EXPERIMENTAL
Intervention: Dissemination strategies including multi-day in-person training workshops, electronic information exchange modalities, and remote technical assistance.
Number of subjects: 12
Study 24330729 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 12
Study 22174811 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg per day of monomeric and oligomeric flavanols (MOF) from grape seeds
Number of subjects: 28
Study 22174811 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 19224815 — intervention group
Group type: EXPERIMENTAL
Intervention: Hegu group (capsicum plaster at Hegu acupoints)
Number of subjects: 84
Study 19224815 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham group (capsicum plaster on shoulders)
Number of subjects: 84
Study 19224815 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo tape at Hegu acupoints and on shoulders)
Number of subjects: 84
Study 19224815 — intervention group
Group type: EXPERIMENTAL
Intervention: Hegu group
Number of subjects: 84
Study 16874418 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocetirizine 5 mg
Number of subjects: 30
Study 16874418 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 12775425 — intervention group
Group type: EXPERIMENTAL
Intervention: Topotecan treatment
Number of subjects: 11
Study 10851363 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated estrogen (Premarin) 1.25 mg/day for 12 weeks
Number of subjects: 50
Study 10851363 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 9036414 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivationally supplemented diabetes training
Number of subjects: 43
Study 9036414 — intervention group
Group type: COMPARATOR
Intervention: Regular teaching programme
Number of subjects: 43
Study 1532762 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental letter designed to increase perceived control
Number of subjects: 71
Study 1532762 — intervention group
Group type: COMPARATOR
Intervention: Routine appointment letter (control)
Number of subjects: 71
Study 6438690 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 97
Study 6438690 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 97
Study 6438690 — intervention group
Group type: EXPERIMENTAL
Intervention: Hamilton Depression Scale (HDS)
Number of subjects: 97
Study 6438690 — intervention group
Group type: EXPERIMENTAL
Intervention: HDS subscale scores
Number of subjects: 97
Study 6438690 — intervention group
Group type: EXPERIMENTAL
Intervention: Percentage of patients changing categories
Number of subjects: 97
Study 30278260 — intervention group
Group type: COMPARATOR
Intervention: Didactic learning alone
Number of subjects: 30
Study 30278260 — intervention group
Group type: EXPERIMENTAL
Intervention: Didactic learning + experiential learning
Number of subjects: 30
Study 30278260 — intervention group
Group type: EXPERIMENTAL
Intervention: Final evaluation after 6 months
Number of subjects: 30
Study 30420353 — intervention group
Group type: EXPERIMENTAL
Intervention: Care manager (CM) programme, 3 months of contact, n=163
Number of subjects: 342
Study 30420353 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (CAU), 3 months of contact, n=179
Number of subjects: 342
Study 30420353 — intervention group
Group type: EXPERIMENTAL
Intervention: Care manager (CM) programme, 6-month costs
Number of subjects: 342
Study 26076387 — intervention group
Group type: EXPERIMENTAL
Intervention: I-gel (IG)
Number of subjects: 120
Study 26076387 — intervention group
Group type: COMPARATOR
Intervention: LMA-Fastrach (FT)
Number of subjects: 120
Study 23955928 — intervention group
Group type: EXPERIMENTAL
Intervention: SASA! community-mobilization intervention
Number of subjects: 1206
Study 21950001 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic thyroidectomy
Number of subjects: 109
Study 21950001 — intervention group
Group type: COMPARATOR
Intervention: Open thyroidectomy
Number of subjects: 109
Study 19671367 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticotrophin
Number of subjects: 0
Study 19671367 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19671367 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone (IVMP)
Number of subjects: 0
Study 19671367 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed IVMP
Number of subjects: 0
Study 17334239 — intervention group
Group type: EXPERIMENTAL
Intervention: Active impedance threshold device
Number of subjects: 9
Study 17334239 — intervention group
Group type: COMPARATOR
Intervention: Sham impedance threshold device (control)
Number of subjects: 9
Study 15368131 — intervention group
Group type: EXPERIMENTAL
Intervention: J‐VAC drainage
Number of subjects: 57
Study 15368131 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulmer drain with drain shortening (Ulmer‐with)
Number of subjects: 57
Study 15368131 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulmer drain without drain shortening (Ulmer‐without)
Number of subjects: 57
Study 11795352 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/day
Number of subjects: 10101
Study 11795352 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10101
Study 9521334 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab therapy and low-dose, weight-adjusted heparin
Number of subjects: 326
Study 9521334 — intervention group
Group type: COMPARATOR
Intervention: Placebo and standard-dose heparin
Number of subjects: 326
Study 9521334 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab therapy
Number of subjects: 326
Study 9889654 — intervention group
Group type: EXPERIMENTAL
Intervention: Pragmatic randomized trials
Number of subjects: 0
Study 9889654 — intervention group
Group type: EXPERIMENTAL
Intervention: Quasi-experimental studies
Number of subjects: 0
Study 9889654 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized controlled trials (RCTs)
Number of subjects: 0
Study 1928811 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilevalol 60 mg
Number of subjects: 10
Study 1928811 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 6897633 — intervention group
Group type: COMPARATOR
Intervention: Continuous chlorambucil/prednisolone therapy (A)
Number of subjects: 118
Study 6897633 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous low-dose prednimustine (B)
Number of subjects: 118
Study 6897633 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent high-dose prednimustine (C)
Number of subjects: 118
Study 6897633 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (A, B, C)
Number of subjects: 118
Study 6897633 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednimustine
Number of subjects: 118
Study 6897633 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment schedule C (Intermittent high-dose prednimustine)
Number of subjects: 118
Study 31828050 — intervention group
Group type: EXPERIMENTAL
Intervention: UWHC protocol (n = 119 sampling events)
Number of subjects: 248
Study 31828050 — intervention group
Group type: COMPARATOR
Intervention: CDC protocol (n = 129 sampling events)
Number of subjects: 248
Study 31828050 — intervention group
Group type: EXPERIMENTAL
Intervention: UWHC protocol
Number of subjects: 248
Study 31828050 — intervention group
Group type: COMPARATOR
Intervention: CDC protocol
Number of subjects: 248
Study 30587149 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation intervention
Number of subjects: 0
Study 30587149 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior assessments completed
Number of subjects: 0
Study 27305192 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF) 300 mg per day from 30 to 32 weeks of gestation until postpartum week 4
Number of subjects: 200
Study 27305192 — intervention group
Group type: COMPARATOR
Intervention: Usual care without antiviral therapy
Number of subjects: 200
Study 27305192 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF)
Number of subjects: 200
Study 25216842 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose combinations (FDCs)
Number of subjects: 1585
Study 25216842 — intervention group
Group type: COMPARATOR
Intervention: Separate drugs
Number of subjects: 1585
Study 23288176 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training with threshold IMT
Number of subjects: 47
Study 23288176 — intervention group
Group type: COMPARATOR
Intervention: Conventional physiotherapy
Number of subjects: 47
Study 20234158 — intervention group
Group type: COMPARATOR
Intervention: Intermittent Pneumatic Compression (IPC)
Number of subjects: 20
Study 20234158 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Low-Molecular-Weight Heparin (LMWH) and IPC
Number of subjects: 20
Study 19284086 — intervention group
Group type: EXPERIMENTAL
Intervention: Newly generated prediction score for myocardial infarction (MINF SCORE)
Number of subjects: 208
Study 19284086 — intervention group
Group type: COMPARATOR
Intervention: Components of the score individually analyzed
Number of subjects: 208
Study 15818697 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (3 mg/kg or 10 mg/kg every 4 or 8 weeks) plus methotrexate (MTX)
Number of subjects: 0
Study 15818697 — intervention group
Group type: COMPARATOR
Intervention: MTX plus placebo
Number of subjects: 0
Study 15818697 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab plus MTX
Number of subjects: 0
Study 12438829 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic implantation of a defibrillator
Number of subjects: 0
Study 12438829 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrophysiologic testing
Number of subjects: 0
Study 9849280 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 1.0 mg.kg‐1
Number of subjects: 318
Study 9849280 — intervention group
Group type: COMPARATOR
Intervention: Suxamethonium 1.0 mg.kg‐1
Number of subjects: 318
Study 7815983 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorbitol (25 g)
Number of subjects: 25
Study 7815983 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose (25 g)
Number of subjects: 25
Study 7815983 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol (25 g)
Number of subjects: 25
Study 3402183 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral propranolol (2 x 80 mg/day)
Number of subjects: 7
Study 3402183 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 31655890 — intervention group
Group type: EXPERIMENTAL
Intervention: CBD/THC oil (low dose for the first 2 weeks, adjusted to a higher dose for the following 2 weeks)
Number of subjects: 6
Study 31655890 — intervention group
Group type: EXPERIMENTAL
Intervention: CBD/THC oil
Number of subjects: 6
Study 29635488 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (40 mg)
Number of subjects: 27
Study 29635488 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 27
Study 28966878 — intervention group
Group type: EXPERIMENTAL
Intervention: Digitizing tablet
Number of subjects: 18
Study 28966878 — intervention group
Group type: EXPERIMENTAL
Intervention: Fahn-Tolosa-Marín (FTM) ratings
Number of subjects: 18
Study 28966878 — intervention group
Group type: COMPARATOR
Intervention: FTM ratings and digitizing tablet
Number of subjects: 18
Study 24709470 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole prophylaxis
Number of subjects: 2017
Study 24709470 — intervention group
Group type: COMPARATOR
Intervention: Control (no antifungal prophylaxis)
Number of subjects: 2017
Study 24669597 — intervention group
Group type: COMPARATOR
Intervention: Pan Retinal Photocoagulation (PRP)
Number of subjects: 54
Study 24669597 — intervention group
Group type: EXPERIMENTAL
Intervention: Pan Retinal Photocoagulation plus Intra Vitreal Bevacizumab (PRP-plus)
Number of subjects: 54
Study 19923377 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g CLA/d (2.5 g c9,t11 CLA/d and 0.6 g trans-10,cis-12 CLA/d)
Number of subjects: 401
Study 19923377 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 401
Study 18082206 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% transdermal dihydrotestosterone gel daily for 3 months (group 1)
Number of subjects: 75
Study 15871014 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium citrate preparation
Number of subjects: 120
Study 15871014 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 14569404 — intervention group
Group type: EXPERIMENTAL
Intervention: Carob pulp preparation (15 g/d)
Number of subjects: 58
Study 10389803 — intervention group
Group type: EXPERIMENTAL
Intervention: OND pretreatment (4 mg in 2 mg/mL solution)
Number of subjects: 80
Study 10389803 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline pretreatment
Number of subjects: 80
Study 8885711 — intervention group
Group type: EXPERIMENTAL
Intervention: Handle rotation task with no precision demands
Number of subjects: 0
Study 8885711 — intervention group
Group type: EXPERIMENTAL
Intervention: Handle rotations ending at or near the end of the range of motion
Number of subjects: 0
Study 8885711 — intervention group
Group type: EXPERIMENTAL
Intervention: Oscillation in the supination part of the forearm rotation range
Number of subjects: 0
Study 8885711 — intervention group
Group type: EXPERIMENTAL
Intervention: Oscillation in the middle part of the range
Number of subjects: 0
Study 8885711 — intervention group
Group type: EXPERIMENTAL
Intervention: Oscillation in the pronation part of the range
Number of subjects: 0
Study 1428773 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin and Ethamsylate combination therapy
Number of subjects: 0
Study 1428773 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin alone
Number of subjects: 0
Study 1428773 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 4010979 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental exercise program
Number of subjects: 35
Study 4010979 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 35
Study 30464446 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal high flow (NHF) 20 L/min
Number of subjects: 17
Study 30464446 — intervention group
Group type: COMPARATOR
Intervention: Supplemental O2 2 L/min
Number of subjects: 17
Study 27562742 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrase inhibitor regimen (elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate)
Number of subjects: 575
Study 27562742 — intervention group
Group type: COMPARATOR
Intervention: Protease inhibitor based regimen (ritonavir-boosted atazanavir with emtricitabine and tenofovir disoproxil fumarate)
Number of subjects: 575
Study 27562742 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrase inhibitor regimen
Number of subjects: 575
Study 27562742 — intervention group
Group type: COMPARATOR
Intervention: Protease inhibitor based regimen
Number of subjects: 575
Study 24753237 — intervention group
Group type: EXPERIMENTAL
Intervention: Brace group (n = 113)
Number of subjects: 340
Study 24753237 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular training group (n = 107)
Number of subjects: 340
Study 24753237 — intervention group
Group type: COMPARATOR
Intervention: Combined intervention group (n = 120)
Number of subjects: 340
Study 22580040 — intervention group
Group type: EXPERIMENTAL
Intervention: Morinda citrifolia aqueous fruit extract (AFE)
Number of subjects: 20
Study 22580040 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopoletin (equivalent dose present in AFE)
Number of subjects: 20
Study 22580040 — intervention group
Group type: COMPARATOR
Intervention: Control (drinking water)
Number of subjects: 20
Study 20352506 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary care physicians received SP verbal feedback, academic detailing, and web-based tutorial
Number of subjects: 73
Study 20352506 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized patient (SP) encounters
Number of subjects: 73
Study 20352506 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient involvement in care
Number of subjects: 73
Study 18027539 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral naltrexone 100 microg (Group A)
Number of subjects: 15
Study 18027539 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral naltrexone 10 microg (Group B)
Number of subjects: 15
Study 18027539 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group C)
Number of subjects: 15
Study 16194199 — intervention group
Group type: EXPERIMENTAL
Intervention: Wilfactin (VWF concentrate with low FVIII content)
Number of subjects: 25
Study 16194199 — intervention group
Group type: COMPARATOR
Intervention: Wilfactin
Number of subjects: 25
Study 16194199 — intervention group
Group type: COMPARATOR
Intervention: FVIII/VWF concentrates
Number of subjects: 25